Morning Overview on MSN
A targeted pill and a custom mRNA vaccine are both beating back pancreatic cancer in early trials — cracking open one of medicine’s hardest tumors
Pancreatic ductal adenocarcinoma has a five-year survival rate of roughly 13 percent, according to the American Cancer ...
Engineers from the University of Houston, MIT and Harvard have developed a new mRNA-based strategy that dramatically amplifies the T-cell response to vaccines - an advance that could lead to far more ...
Morning Overview on MSN
Two new pancreatic cancer treatments — a targeted pill and a personalized mRNA vaccine — are beating back one of medicine’s deadliest tumors in early trials
Pancreatic cancer has long been oncology’s most stubborn adversary. Fewer than 13% of patients survive five years after ...
Pancreatic cancer remains one of the most difficult cancers to treat, with many patients facing a high risk of recurrence even after surgery and chemotherapy. Researchers are now exploring ...
UH engineers helped develop an mRNA-based strategy that boosts cancer-fighting T cells and, in mouse studies, helped ...
Covid vaccines may come with a tantalizing benefit that has nothing to do with the virus they’re designed to protect against: boosting the immune system to better fight tumors during cancer treatment.
Donna Gustafson had a harder time than usual shaking off the jet lag from her 22-hour journey from Florida to Australia. Two days into her trip, her skin took on the yellow hue of jaundice. Subscribe ...
Ongoing federal support for mRNA technology and research could make good on a longstanding presidential promise to cure cancer, according to Jeff Coller, Bloomberg Distinguished Professor of RNA ...
A University of Florida research team led by Elias Sayour, M.D., Ph.D., (center) developed an mRNA vaccine that boosted the tumor-fighting effects of immunotherapy in a mouse-model study. Provided by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results